Fig. 7: Phenotypes of the mAkt/FoxoQKO mice.

a–e, j Body weight (n = 7 or 12 mice per group, as shown by the number of data points on the graph, same as below) (a), lean body mass analyzed by systemic CT scanning (n = 5 or 6 mice) (b), c, j tissue weight (n = 5 or 7 mice), d grip strength (n = 5 or 7 mice), and e exercise duration (n = 5 or 7 mice), of the mAkt/FoxoQKO mice at the age of 52 weeks. f, g Gene expression (f), and DNA copy number, of EDL at the age of 52 weeks analyzed by RT-PCR (n = 5 or 7 mice) (g). h Electron microscopic image of vertical sectioning of EDL at the age of 52 weeks. Scale bars: 500 nm. i Area under the curve (AUC) of relative plasma glucose (PG) in insulin tolerance test (ITT) after intraperitoneal injection of human regular insulin (1.0 U/kg BW) at the age of 40 weeks (n = 7 or 12 mice). k Analysis of osteoporosis by micro-CT scanning of femur at the age of 52 weeks (n = 5 or 7 mice). l Kaplan–Meire curve for survival (n = 18 or 38 mice). m, n Scatter plot of dead body weight (m), and cause of death, of mice whose dead body was retrieved without deterioration (n = 17 or 38 mice) (n). o Skeletal muscle weight of the mAktDKO mice at the age of 90 weeks treated with AS1842856 at the dose of 100 mg/kg of BW daily for 4 weeks (n = 4 or 5 mice). bCD: β-cyclodextrin, AS: AS1842856. Values of the data are expressed as mean ± SEM except in (l–n). Unpaired 2-tailed t-test (a–g, i–k, m, o), logrank test (l), and Chi-square test with Yates’ correction (n) were used for assessment respectively, and the exact P values are provided in Supplementary Data 2. Source data are provided as a Source Data file.